耐受性
医学
不利影响
安慰剂
内科学
他克莫司
恶心
胃肠病学
心脏病学
肺动脉高压
病理
移植
替代医学
作者
Edda F. Spiekerkoetter,Yon K. Sung,Deepti Sudheendra,Valerie K. Scott,Patricia A. del Rosario,Matthew A. Bill,François Haddad,Janel Renee Long-Boyle,Haley Hedlin,Roham T. Zamanian
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2017-09-01
卷期号:50 (3): 1602449-1602449
被引量:192
标识
DOI:10.1183/13993003.02449-2016
摘要
Pulmonary arterial hypertension (PAH) is a devastating disease characterised by occlusive pulmonary vasculopathy. Activation of bone morphogenetic protein receptor 2 (BMPR2) signalling by FK506 (tacrolimus) reverses occlusive vasculopathy in rodent PAH models. Here, we determined the safety and tolerability of low-level FK506 therapy in stable PAH patients. We performed a randomised, double-blind, placebo-controlled, 16-week, single-centre, phase IIa trial in PAH patients with New York Heart Association functional class II/III symptoms using three FK506 target levels (<2, 2–3 and 3–5 ng·mL −1 ). 23 patients were randomised and 20 patients completed the trial. FK506 was generally well tolerated, with nausea/diarrhoea being the most commonly reported adverse event and no observation of line infections in patients on intravenous prostacyclin therapy. PAH patients had significantly lower BMPR2 expression in peripheral blood mononuclear cells versus healthy controls (n=13; p=0.005), which improved after FK506 treatment. While we observed that some patients responded with a pronounced increase in BMPR2 expression as well as improvement in 6-min walk distance, and serological and echocardiographic parameters of heart failure, these changes were not significant. Low-level FK506 is well tolerated and increases BMPR2 in subsets of PAH patients. These results support the study of FK506 in a phase IIb efficacy trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI